چکیده: (86 مشاهده)
Background: The effect of damask rose on lowering blood pressure has been investigated, and findings suggest a potential beneficial impact on reducing both systolic and diastolic blood pressure; however, the available data are not yet conclusive. This meta-analysis was conducted to provide a more precise estimate of the effect of damask rose on systolic and diastolic blood pressure in adults.
Methods: The databases Scopus, PubMed, Web of Science Core Collection, Embase, CENTRAL, ProQuest, CINAHL, SID, and MagIran were systematically searched to identify relevant studies published prior to July 2024 that evaluated the impact of damask rose on systolic and diastolic blood pressure. From an initial yield of 678 records, five randomized controlled trials (RCTs) were deemed eligible for inclusion. The methodological quality of these trials was assessed using the Cochrane risk-of-bias tool. Where data permitted, a meta-analysis was conducted using a random-effects model in Stata software (version 11.2); otherwise, findings were summarized narratively. Continuous outcomes were pooled and expressed as standardized mean differences with 95% confidence intervals (95% CI).
Results: A total of five randomized controlled trials (RCTs), comprising a combined sample of 410 participants, were included in this meta-analysis. When comparing the intervention groups (receiving Damask rose products) with the control groups, the pooled effect size showed no statistically significant reduction in either systolic or diastolic blood pressure. For systolic blood pressure (SBP), the standardized mean difference (SMD) was -0.49 (95% confidence interval: -1.18 to 0.20, P = 0.16). For diastolic blood pressure (DBP), the SMD was -0.11 (95% CI: -0.51 to 0.28, P = 0.57). Significant and substantial heterogeneity was observed among the studies for both outcomes (SBP: I² = 88%, P < 0.01; DBP: I² = 93%, P < 0.01), indicating high inconsistency in effect sizes.
Conclusion: The administration of damask rose may not be associated with changes in systolic and diastolic blood pressure in adults. Given the paucity of available evidence, further studies are required to confirm these findings.
Methods: The databases Scopus, PubMed, Web of Science Core Collection, Embase, CENTRAL, ProQuest, CINAHL, SID, and MagIran were systematically searched to identify relevant studies published prior to July 2024 that evaluated the impact of damask rose on systolic and diastolic blood pressure. From an initial yield of 678 records, five randomized controlled trials (RCTs) were deemed eligible for inclusion. The methodological quality of these trials was assessed using the Cochrane risk-of-bias tool. Where data permitted, a meta-analysis was conducted using a random-effects model in Stata software (version 11.2); otherwise, findings were summarized narratively. Continuous outcomes were pooled and expressed as standardized mean differences with 95% confidence intervals (95% CI).
Results: A total of five randomized controlled trials (RCTs), comprising a combined sample of 410 participants, were included in this meta-analysis. When comparing the intervention groups (receiving Damask rose products) with the control groups, the pooled effect size showed no statistically significant reduction in either systolic or diastolic blood pressure. For systolic blood pressure (SBP), the standardized mean difference (SMD) was -0.49 (95% confidence interval: -1.18 to 0.20, P = 0.16). For diastolic blood pressure (DBP), the SMD was -0.11 (95% CI: -0.51 to 0.28, P = 0.57). Significant and substantial heterogeneity was observed among the studies for both outcomes (SBP: I² = 88%, P < 0.01; DBP: I² = 93%, P < 0.01), indicating high inconsistency in effect sizes.
Conclusion: The administration of damask rose may not be associated with changes in systolic and diastolic blood pressure in adults. Given the paucity of available evidence, further studies are required to confirm these findings.
نوع مقاله: مروری |
| بازنشر اطلاعات | |
 |
این مقاله تحت شرایط Creative Commons Attribution-NonCommercial 4.0 International License قابل بازنشر است. |